Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial of Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Press/Media

Period10 Feb 2020

Media coverage

1

Media coverage

  • TitleIcahn School of Medicine at Mount Sinai Listed a New Clinical Trial of Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date10/02/20
    PersonsRajwanth Veluswamy
View all 1
View less